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between 1997 and 2006 was conducted. Elderly patients with
continuous health plan coverage,  drug prescription per calen-
dar year, and  diagnosis for 1) asthma; 2) cancer; or 3) cardio-
vascular disease (CVD) were selected. Drug vintage, deﬁned as
the ingredient’s earliest marketed date, was drawn from Health
Canada Drug Product Database. A multivariate analysis was
conducted to estimate the impact of drug vintage on patients’
probability of dying using time-varying Cox proportional hazard
model. The covariates used for adjustment in the regression
model were: demographics characteristics, guaranteed income
supplement (GIS) status, medical resources utilization, concomi-
tant drug utilization, and comorbidities. RESULTS: A total of
6912, 12,341, and 29,394 elderly subjects formed the asthma,
cancer, and CVD study populations, respectively, of which 1220
(18%), 3479 (28%), and 6043 (21%) died during the observa-
tion period. Overall, mean age was 68 years; 49% of subjects
were women. After controlling for confounding factors, the use
of recent medications (i.e. Post-1990 ingredients) was consis-
tently associated with a signiﬁcant risk reduction of mortality
(hazard ratios <1.0, p < 0.0001 for all disease areas), relative to
older ingredients, suggesting that recent drug innovation had a
signiﬁcant beneﬁcial impact on longevity in patients with asthma,
cancer, or CVD. Other covariates associated with an increased
risk of mortality included age, gender, GIS beneﬁciaries, hospi-
talization, and number of comorbidities. CONCLUSION: This
analysis showed that drug innovation, in particular medications
launched after 1990, had a signiﬁcant beneﬁcial impact on lon-
gevity of elderly patients in three important disease areas.
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OBJECTIVE: Safety, efﬁcacy, and ﬁnancial concerns are impor-
tant considerations when evaluating the reasons for market
discontinuation of drugs. In this study, market discontinuation
of new chemical entities (NCEs) approved by the FDA in the
period 1980–2007 were analyzed according to therapeutic class,
regulatory changes, orphan drug status, and priority review.
METHODS: Data was derived from the FDA, Micromedex and
Medline. A drug was considered discontinued if deleted from
the FDA’s Orange book. Withdrawals of approval were also
included in the study. Descriptive statistics and chi-square tests
were performed. RESULTS: A total of 703 NCEs were approved
during the study period. In December 31, 2007, 71.8% NCEs
remained in the market; 14.9% were discontinued; 5.4% NCES
had the brand discontinued, but the generic was available; 7.0%
had changes in route, dosage form or strength; and 0.9% were
over-the-counter drugs. Safety was the primary reason for with-
drawal of 30 (4.3%) NCEs; 14 (2.0%) NCEs had Federal Reg-
ister determination for not being discontinued for safety or
efﬁcacy reasons; and 61 (8.7%) had no reasons stated by the
FDA. Compared to other classes antibiotics were more likely
(p < 0.05) to be discontinued. Analyses of priority review, orphan
drug status, and the sponsor company’s country (US or non-US)
with respect to market withdrawal were not signiﬁcant. Com-
parisons of pharmaceuticals withdrawn due to safety reasons
with therapeutic class and implementation of Prescription Drug
User Fee Act were also not signiﬁcant. CONCLUSION: One in
seven NCEs approved during the study period were discontinued
from the market. A small percentage of drugs were discontinued
due to safety or ﬁnancial reasons. An ongoing evaluation of
NCEs in the market place is important to determine which prod-
ucts provide optimal beneﬁts in terms of efﬁcacy, safety, and
value compared to other products overall and other products
within the same therapeutic class.
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OBJECTIVE: The U.S. Medicare drug beneﬁt (Part D) was
implemented in January 2006 to reduce cost-related underuse of
medications, experienced by 25% of older patients in the US.
This study evaluated the impact of Part D on medication use
patterns and cost-savings for subsequent medical services.
METHODS: We collected all claims of 20,645 members from a
large Medicare managed care plan between January 1, 2005 and
December 31, 2006. We used a time series and comparison group
design to measure the changes in outcomes before and after Part
D. Intervention group included members who had no drug cov-
erage or quarterly caps in drug spending and whose coverage
became more generous after Part D. The comparison group had
no limits on drug spending before and after Part D. We estimated
the impact of Part D on 1) out-of-pocket pharmacy spending and
non-drug medical spending using generalized linear models;
2) number of monthly drug scripts, medication adherence, and
counts of hospitalization and ED visits using Poisson regressions;
and 3) adherence for antihypertensive, lipid-lowering, anti-
diabetic, and antipsychotic agents using generalized-estimating-
equation models. RESULTS: Part D reduced out-of-pocket
expenditures by 20%–50% depending on members’ drug limits.
Part D increased number of monthly drug scripts by 0.5, among
members without drug coverage who prescribed 3 scripts per
month and members with quarterly $150 cap who prescribed
about 3.5 monthly scripts in 2005. We did not ﬁnd improve-
ments on medication adherence for selected drug classes. We
found total medical and inpatient spending reduced by 10% (not
statistically signiﬁcant) for members who had a previous $625
quarterly cap. We did not ﬁnd any cost offsets for members with
other drug limits. CONCLUSION: Part D decreased out-of-
pocket pharmacy expenditures and increased demand for drugs
but did not induce savings from subsequent medical services.
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OBJECTIVE: Since the implementation of Medicare Part D,
numerous anecdotal descriptions and a few small studies have
reported low reimbursements to community pharmacies. The
purpose of this study was to quantitatively assess the impact of
Medicare Part D on percent gross margin earned by independent
pharmacies in Texas using prescription claims data collected by a
pharmacy claims switching company for dual eligible beneﬁcia-
ries. METHODS: The study evaluated a total of 457,611 claims
for prescriptions dispensed in the fourth quarter of 2005
(n = 152,521) and the second and third quarters of 2006
(n = 305,090). The prescriptions were dispensed by 313 indepen-
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dent pharmacies in Texas to 24,576 dual eligible patients. Percent
gross margin was compared between Medicaid and Medicare
Part D claims as well as among several popular Prescription Drug
Plan (PDP) sponsor claims. RESULTS: The mean percent gross
margin for prescriptions dispensed before Part D (Medicaid
claims) was 26.7%. The mean percent gross margin for claims
dispensed after Part D (Medicare claims) was 17.0% (using
ingredient costs in 2006 dollars) or 20.4% (using ingredient costs
adjusted to 2005 dollars), a reduction of 36.3% and 23.6%,
respectively. Among the ﬁve PDP sponsors identiﬁed as having
the greatest number of claims in the sample, the mean percent
gross margin ranged from 12.0% to 19.8%. Regression analysis
conﬁrmed that the PDP sponsor, in addition to the proportion of
generic drugs dispensed, is a signiﬁcant predictor of a pharmacy’s
overall percent gross margin. CONCLUSION: These ﬁndings
support pharmacy assertions of lower reimbursements from
Medicare Part D payers compared with Medicaid payers. Based
on these ﬁndings, pharmacies can respond to this new environ-
ment by accepting Part D plans with higher average percent gross
margins and increasing the proportion of generic drugs dispensed
to Medicare beneﬁciaries.
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OBJECTIVE: The standard Medicare Part D beneﬁt includes a
“doughnut hole” in coverage. Standard beneﬁt beneﬁciaries who
fall into this gap are responsible for the total costs of their
prescription drugs. The objective of this study was to evaluate the
impact of doughnut hole on the use of medications by therapeu-
tic classes. METHODS: A difference-in-difference (DID) study
approach was used. De-identiﬁed data from January 1, 2006 to
December 31, 2006 were obtained from a pharmacy beneﬁt
management database. The study group included standard
beneﬁt beneﬁciaries who reached the doughnut hole in a time
period from June 1 to October 31, 2006. The control group
included beneﬁciaries enrolled in commercial prescription drug
plans without coverage gaps. Changes in prescription days per
month, out-of-pocket costs per month, and generic utilization
rates by therapeutic classes were targeted outcome measures.
RESULTS: After controlling for demographics, disease condi-
tions and secular trend of drug use, the Part D doughnut hole was
found to be associated with reductions in use of antiasthmatics
(-3.08 prescription days per month, p < 0.0001), antineoplastics
(-2.70, p < 0.0001), antipsychotics (-1.77, p = 0.0630), anti-
diabetic drugs (-1.63, p = 0.0010), anticonvulsants (-1.49,
p = 0.0042), antidepressants (-1.11, p = 0.0011), antihyperlipi-
demics (-1.09, p < 0.0001), but slight increase in use of antivirals
(0.08, p = 0.9011) and opioid analgesics (0.05, p = 0.8503). The
Part D doughnut hole was also associated with signiﬁcant
increases in the average out-of-pocket costs for all therapeutic
classes and increases in generic utilization rates for all classes
except opioid analgesics. CONCLUSION: Standard Part D ben-
eﬁciaries in the doughnut hole signiﬁcantly reduced use of medi-
cations for potentially disabling and life-threatening conditions,
but increased spending on medications for potentially less life-
threatening conditions. This raises concern for an increased risk
of adverse health events.
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OBJECTIVE: To examine the changes in Medicare Part B drug
utilization and expenditures associated with the reduction in
physician reimbursement for Part B drugs between 2003 and
2005 and availability of drug alternatives through Medicare Part
D in 2006. This study speciﬁcally focuses on Part B biologics for
rheumatoid arthritis (RA) since they faced both these changes
introduced by the Medicare Modernization Act(MMA) of 2003.
METHODS: We used the 2002 to 2006 Medicare 5% ﬁles which
contain fee-for-service claims and enrollment data for a 5%
random sample of the Medicare population. We examined ben-
eﬁciaries with an RA diagnosis (ICD-9-CM 714.xx) in each year.
Inﬂiximab, the only Part B covered RA biologic available pre-
MMA, was identiﬁed using HCPCS codes. We tracked national
trends in its prevalence of use, number of claims, and total
payments(in 2004 dollars) across 2002 to 2006. Multivariate
regressions with standard errors corrected for repeated observa-
tions were estimated. RESULTS: We identiﬁed 0.65 to 0.81
million RA patients in 2002 to 2006. The prevalence of inﬂix-
imab use increased from 4.6% to 5.8% between 2002 and 2004
and then declined to 5.0% in 2005 and 5.2% in 2006 (p < 0.05).
The number of inﬂiximab claims per user increased from 2002 to
2004 (p < 0.05); however, there was no signiﬁcant change across
2004 to 2006. As expected, the average payment per claim
reduced by 10% from 2004 to 2005. As a result, total payments
for inﬂiximab declined from $512 million in 2004 to $459
million in 2005. Total payments per user reduced from $12,443
in 2004 to $11,194 in 2005 (p < 0.05). There was no signiﬁcant
difference in any payment measure between 2005 and 2006.
Adjusted analyses conﬁrmed these ﬁndings. CONCLUSION:
Inﬂiximab use and expenditures declined modestly after the
introduction of the average sales price based reimbursement
system in 2005. No changes were observed after the introduction
of Medicare Part D in 2006.
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OBJECTIVE: To examine the real world impact of antipsychotics
onweight gain in adolescent patients (12–19 years) taking second-
generation (SGA) or ﬁrst-generation antipsychotics (FGA).
METHODS: Naïve monotherapy patients receiving FGA’s or
SGA’s between July 1999 and March 2006 were identiﬁed using
the GE Centricity electronic medical record database; patients on
clozapine or depot antipsychotics were excluded. Baseline Body
Mass Index (BMI) recorded within 90 days prior and closest to
index prescription date was compared with maximum BMI
obtained during the follow-up period (at least 90 days to end of
study period or monotherapy period). Multivariate linear and
logistic regressions were conducted to estimate the magnitude of
weight gain and odds of 5%, 10%, 15%, and 20% increase in
BMI. To account for growth, BMI was normalized by calculating
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